Scott Schliebner | Vice President, Scientific Affairs, Rare Diseases

Scott Schliebner, Vice President, Scientific Affairs, Rare Diseases, PRA

Mr. Schliebner is a clinical scientist by training, with a 20-year background in clinical drug development.  His expertise is focused on providing strategic, scientific and operational guidance to clients on clinical trial design, competitive landscape analysis, investigator selection, advocacy group engagement, and operational considerations to effectively execute rare disease clinical trials. Prior to building PRA Health Sciences’ focus on rare diseases, Mr. Schliebner served as the Chief Operating Officer for a niche oncology research organization focused on accelerating the development of targeted cancer therapies for rare tumor types.  Mr. Schliebner regularly speaks on the topic of rare disease clinical development, and serves on the Drug Information Association’s (DIA’s) Rare Disease Program Committee.  His white papers and podcasts have focused on leveraging medical informatics, multi-stakeholder engagement, and incorporating the patient/caregiver voice into the rare disease clinical trial process.  He serves on the Board of several local non-profit organizations and holds a master’s degree in public health, focused on epidemiology and biostatistics, from the University of Utah School of Medicine.


World Orphan Drug Congress USA 2018 - Conference Day One @ 14:33

ROUNDTABLE 3: Virtual Trials - enabling clinical trials to be more virtual, reducing distance times, overcoming geographic barriers and increasing data collection through the use of wearables

World Orphan Drug Congress USA 2018 - Conference Day Two @ 14:04

ROUNDTABLE 4: Gene Therapy trials- Overcoming the challenges of conducting gene therapy studies and navigating the regulatory landscape

back to speakers